Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration.
about
Low-molecular-weight heparins: are they all the same?Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgeryInfluence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.
P2860
Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Tissue factor and tissue facto ...... weight heparin administration.
@en
Tissue factor and tissue facto ...... weight heparin administration.
@nl
type
label
Tissue factor and tissue facto ...... weight heparin administration.
@en
Tissue factor and tissue facto ...... weight heparin administration.
@nl
prefLabel
Tissue factor and tissue facto ...... weight heparin administration.
@en
Tissue factor and tissue facto ...... weight heparin administration.
@nl
P2093
P2860
P1476
Tissue factor and tissue facto ...... weight heparin administration.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2141.2002.03522.X
P407
P577
2002-06-01T00:00:00Z